<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon syndrome</z:e>--cerebrovascular lesions and <z:e sem="disease" ids="C0085642" disease_type="Disease or Syndrome" abbrv="">livedo racemosa</z:e>--is a distinctive and uncommon disorder delineated by Sneddon in 1965 </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical hallmarks are generalized <z:e sem="disease" ids="C0085642" disease_type="Disease or Syndrome" abbrv="">livedo racemosa</z:e> and central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Cutaneous vascular changes begin with intimal endothelial proliferation and fibromucinous matrix formation, leading to obstruction and obliteration of the vessel </plain></SENT>
<SENT sid="3" pm="."><plain>The disorder is <z:hpo ids='HP_0003677'>slowly progressive</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>No effective treatment is available, but platelet-inhibiting agents or newer antithrombotic agents may offer some hope in preventing or minimizing serious sequelae of this disease </plain></SENT>
</text></document>